1157846-22-4Relevant articles and documents
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action
Van Huis, Chad A.,Casimiro-Garcia, Agustin,Bigge, Christopher F.,Cody, Wayne L.,Dudley, Danette A.,Filipski, Kevin J.,Heemstra, Ronald J.,Kohrt, Jeffrey T.,Leadley Jr., Robert J.,Narasimhan, Lakshmi S.,McClanahan, Thomas,Mochalkin, Igor,Pamment, Michael,Thomas Peterson,Sahasrabudhe, Vaishali,Schaum, Robert P.,Edmunds, Jeremy J.
experimental part, p. 2501 - 2511 (2009/09/05)
Aiming to improve upon previously disclosed Factor Xa inhibitors, a series of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides were explored with the intent of increasing the projected human half-life versus 5 (projected human t1/2 = 6 h). A stereospecific route to compounds containing a 4-aryl-4-hydroxypyrrolidine scaffold was developed, resulting in several compounds that demonstrated an increase in the half-life as well as an increase in the in vitro potency compared to 5. Reported herein is the discovery of 26, containing a (2R,4S)-4-hydroxy-4-(2,4-difluorophenyl)-pyrrolidine scaffold, which is a selective, orally bioavailable, efficacious Factor Xa inhibitor that appears suitable for a once-daily dosing (projected human t1/2 = 23 h).